

03-15-2002



Form PTO-1595 (Rev. 03/01) F
OMB No. 0651-0027 (exp. 5/31/2002)
Tab settings

PATENT

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
ImaRx Pharmaceutical Corp.
3.5'02
Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)
Name: DuPont Contrast Imaging Inc.
Internal Address: Legal Department
Street Address: Route 206 & Provinceline Road
City: Princeton State: NJ Zip: 08543-4000
Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other
Execution Date: 10/07/1999

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____
A. Patent Application No.(s) See attached Schedule B
B. Patent No.(s) See attached Schedule A
Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Denise Bierlein
Internal Address: Legal Division
Street Address: Route 141 & Henry Clay Rd.
Experimental Station, E353/133F
City: Wilmington State: DE Zip: 19880-0353

6. Total number of applications and patents involved: 66
7. Total fee (37 CFR 3.41).....\$ 2,640.00
 Enclosed
 Authorized to be charged to deposit account

8. Deposit account number:
023850
MAR - 5 2002

DO NOT USE THIS SPACE

9. Signature.
Denise Bierlein
Name of Person Signing
Denise Bierlein
Signature
02/08/02
Date

Total number of pages including cover sheet, attachments, and documents: 9
Main documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

03/15/2002 AAHMED1 00000007 023850 5123414
01 FC:581 2640.00 CH

PATENT
REEL: 012653 FRAME: 0112

SCHEDULE A
Granted Patents

BMS Docket #	UNGR Docket #	US Patent Number	Grant Date
BMS-0004	UNGR-0088	5,123,414	6/23/92
BMS-0007	UNGR-0301	ABANDONED	2/17/93
BMS-0008	UNGR-0320	5,334,381	8/2/94
BMS-0011	UNGR-0688	5,571,497	11/5/96
BMS-0089	UNGR-0048	5,228,446	7/20/93
BMS-0092	UNGR-0470	5,769,080	6/23/98
BMS-0375	UNGR-0974	5,846,517	1/30/97
BMS-0376	UNGR-1497	6,071,494	6/6/00
BMS-0003	UNGR-0019	5,088,499	2/18/92
BMS-0005	UNGR-0095	5,230,882	7/27/93
BMS-0006	UNGR-0279	5,352,435	10/4/94
BMS-0010	UNGR-0574	5,456,901	10/10/95
BMS-0012	UNGR-0728	6,001,335	12/14/99
BMS-0013	UNGR-1190	5,985,246	11/16/99
BMS-0045	UNGR-0046	5,205,290	4/27/93
BMS-0046	UNGR-0295	5,281,408	1/25/94
BMS-0047	UNGR-0346	5,456,900	10/10/95
BMS-0048	UNGR-0664	5,547,656	8/20/96
BMS-0049	UNGR-0665	5,527,521	6/18/96
BMS-0090	UNGR-0299	5,305,757	4/26/94
BMS-0091	UNGR-0319	5,348,016	9/20/94
BMS-0113	UNGR-0298	5,469,854	11/28/95
BMS-0114	UNGR-0686	5,715,824	2/10/98
BMS-0115	UNGR-0988	5,935,553	8/10/99
BMS-0139	UNGR-0348	5,542,935	8/6/96
BMS-0163	UNGR-0350	5,585,112	12/17/96
BMS-0164	UNGR-0685	5,853,752	12/29/98
BMS-0165	UNGR-1227	6,071,495	6/6/00
BMS-0191	UNGR-0480	5,773,024	6/30/98
BMS-0192	UNGR-0991	6,146,657	11/14/00
BMS-0221	UNGR-0570	5,705,187	1/6/98
BMS-0250	UNGR-0571	5,656,211	8/12/97
BMS-0251	UNGR-1035	6,039,557	3/21/00
BMS-0280	UNGR-0625	5,997,898	12/7/99
BMS-0331	UNGR-0725	6,033,645	3/7/00
BMS-0343	UNGR-0773	5,776,429	7/7/98
BMS-0344	UNGR-1286	6,033,646	3/7/00
BMS-0461	UNGR-1269	6,231,834	5/15/01
BMS-0533	UNGR-0569	5,830,430	11/3/98
BMS-0534	UNGR-0534	6,056,938	5/2/00

SCHEDULE B
Pending Patents

BMS Docket #	UNGR Docket #	US Serial Number	Filing Date
BMS-0009	UNGR-0421	08/163,039	12/6/93
BMS-0366	UNGR-0882	08/712,173	9/11/96
BMS-0051	UNGR-1174	08/878,233	6/18/97
BMS-0093	UNGR-1267	09/000,522	12/30/97
BMS-0140	UNGR-0692	08/485,998	6/7/95
BMS-0166	UNGR-1340	09/118,329	7/17/98
BMS-0192	UNGR-0991	08/741,598	11/1/96
BMS-0193	UNGR-1283	09/052,075	3/31/98
BMS-0222	UNGR-1223	08/947,305	10/8/97
BMS-0306	UNGR-0944	08/660,032	6/6/96
BMS-0307	UNGR-1520	09/218,660	12/22/98
BMS-0332	UNGR-1556	09/290,324	4/12/99
BMS-0344	UNGR-1286	09/026,326	2/19/98
BMS-0399	UNGR-0990	60/031,903	11/25/96
BMS-0400	UNGR-0998	08/800,993	2/20/97
BMS-0437	UNGR-0992	08/915,103	8/20/97
BMS-0438	UNGR-1030	08/915,203	8/20/97
BMS-0439	UNGR-1032	08/796,798	2/6/97
BMS-0440	UNGR-1192	09/033,001	2/26/98
BMS-0441	UNGR-1172	08/929,847	9/15/97
BMS-0461	UNGR-1269	08/982,829	12/2/97
BMS-0462	UNGR-1285	60/073,913	2/6/98
BMS-0463	UNGR-1550	09/243,640	2/3/99
BMS-0510	UNGR-0510	09/573,264	5/18/00
BMS-0558	UNGR-1338	09/075,343	5/11/98
BMS-0596	UNGR-0596	09/901,934	7/10/01

Office of the Secretary of State

I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:


"IMARX PHARMACEUTICAL CORP.", A ARIZONA CORPORATION,
WITH AND INTO "DUPONT CONTRAST IMAGING INC." UNDER THE NAME OF "DUPONT CONTRAST IMAGING INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE SEVENTH DAY OF OCTOBER, A.D. 1999, AT 4:30 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



3098309 8100M

991426277


Edward J. Freel, Secretary of State

0016700

AUTHENTICATION:

10-08-99

DATE:

PATENT
REEL: 012653 FRAME: 0115

CERTIFICATE OF MERGER
OF
IMARX PHARMACEUTICAL CORP.
(an Arizona corporation)
with and into
DUPONT CONTRAST IMAGING INC.
(a Delaware corporation)

Pursuant to Section 252 of the
Delaware General Corporation Law

The undersigned corporations DO HEREBY CERTIFY:

FIRST: That the name and state of incorporation of each of the constituent corporations which is to merge is as follows:

<u>Name</u>	<u>Jurisdiction</u>
ImaRx Pharmaceutical Corp.	Arizona
DuPont Contrast Imaging Inc.	Delaware

SECOND: That an Agreement and Plan of Merger has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the provisions of the Section 252 of the Delaware General Corporation Law. Such approval by the shareholders of ImaRx Pharmaceutical Corp. was obtained at a special meeting of the shareholders held on October 7, 1999. No vote of the stockholders of DuPont Contrast Imaging Inc. was necessary to authorize the merger.

THIRD: That the name of the surviving corporation is DuPont Contrast Imaging Inc.

FOURTH: That the Certificate of Incorporation of DuPont Contrast Imaging Inc., the surviving corporation, as is in effect on the date of the merger provided in the Agreement and Plan of Merger shall continue in full force and effect as the Certificate of Incorporation of the corporation surviving this merger.

FIFTH: That the executed Agreement and Plan of Merger is on file at the principal place of business of DuPont Contrast Imaging Inc., the surviving corporation, at 1007 Market Street, Wilmington, Delaware 19898.

SIXTH: That a copy of the Agreement and Plan of Merger will be furnished by DuPont Contrast Imaging Inc., the surviving corporation, on request and without cost, to any stockholder (or shareholder) of any constituent corporation.

SEVENTH: That the manner of converting the shares of the capital stock of the merged corporation into shares or other securities of E.I. du Pont de Nemours and Company, the parent corporation of the surviving corporation, shall be as follows:

(a) Each share of common stock of the surviving corporation, which shall be issued and outstanding on the effective date of the Agreement and Plan of Merger, shall remain issued and outstanding.


(b) Each share of common stock of the merged corporation which shall be outstanding on the effective date of the Agreement and Plan of Merger, and all rights in respect thereto, shall forthwith be changed and converted into cash and shares of common stock of E.I. du Pont de Nemours and Company.

(c) After the effective date of the Agreement and Plan of Merger, each holder of an outstanding certificate representing the shares of common stock of the merged corporation shall surrender the same to E.I. du Pont de Nemours and Company, the parent corporation of the surviving corporation, and each such holder shall be entitled upon such surrender to receive the number of shares of common stock of E.I. du Pont de Nemours and Company on the basis provided therein. Until so surrendered, the outstanding shares of stock of the merged corporation to be converted into the stock of E.I. du Pont de Nemours and Company as provided therein, may be treated by E.I. du Pont de Nemours and Company and the surviving corporation for all corporate purposes as evidencing the ownership of shares of E.I. du Pont de Nemours and Company as though said surrender and exchange had taken place. After the effective date of the Agreement and Plan of Merger, each registered owner of any uncertificated shares of common stock of the merged corporation shall have said shares cancelled and said registered owner shall be entitled to the number of common shares of E.I. du Pont de Nemours and Company on the basis provided therein.

EIGHTH: The authorized capital stock of ImaRx Pharmaceutical Corp. consists of 5,000,000 shares of common stock, par value \$.01 per share.

IN WITNESS WHEREOF, each of the undersigned has caused this Certificate of Merger to be signed by a duly authorized officer this 7th day of October, 1999.

IMARX PHARMACEUTICAL CORP.

By: 
Name: Evan C. Unger
Title: President and Chief Executive Officer

DUPONT CONTRAST IMAGING INC.


By: _____
Name: Nicholas L. Teti
Title: President

IN WITNESS WHEREOF, each of the undersigned has caused this Certificate of Merger to be signed by a duly authorized officer this 7th day of October, 1999.

IMARX PHARMACEUTICAL CORP.

By: _____
Name: Evan C. Unger
Title: President and Chief Executive Officer

DUPONT CONTRAST IMAGING INC.

By:  _____
Name: Nicholas L. Teti
Title: President

DUPONT CONTRAST IMAGING INC.

Secretary's Certificate

I, Robert Pelzer, secretary of DuPont Contrast Imaging Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certify, as such secretary, that the Agreement and Plan of Merger, after having been first duly signed on behalf of said corporation and having been signed on behalf of ImaRx Pharmaceutical Corp., a corporation of the State of Arizona, was duly adopted pursuant to subsection (f) of Section 251 of Title 8 of the Delaware Code without any vote of the stockholders of said corporation, as the surviving corporation; and that the Agreement and Plan of Merger does not amend in any respect the Certificate of Incorporation of said corporation, as the surviving corporation, and each share of stock of said corporation, as the surviving corporation, outstanding immediately prior to the effect of the merger is to be an identical outstanding or treasury share of the surviving corporation after the effective date of the merger; no shares of common stock of said corporation, as the surviving corporation, and no shares, securities or obligations convertible into such stock shall be issued or delivered under the Agreement and Plan of Merger and that the foregoing were such as to render subsection (f) of Section 251 of Title 8 of the Delaware Code applicable; and that the Agreement and Plan of Merger was thereby adopted by action of the Board of Directors of said DuPont Contrast Imaging Inc., and is the duly adopted agreement and act of said corporation.

IN WITNESS WHEREOF, I have executed this Certificate as of the 7th day of October, 1999.



Name: Robert Pelzer, Secretary

PHL_A 1300104 v 2